Thoughts on getting both Mammaprint and Oncotype DX?

mellee
mellee Member Posts: 434
edited December 2016 in IDC (Invasive Ductal Carcinoma)

I got the Mammaprint and came back as low risk. Wondering what others think about also getting the Oncotype? One oncologist said there's no point, another said it could help because it is based on completely different genetic markers. I do know that their results don't always overlap. I like the idea of knowing where I fall on the continuum.

Anyone here do both? What are your thoughts?

· Share on FacebookShare on Twitter

Comments

  • stephilosphy00
    stephilosphy00 Member Posts: 386
    edited December 2016

    My tumor has similar stat as yours, however because it is grade 3 and I am so young, my MO asked me to do chemo first and I don't have problem with it. I just want to do whatever I can to prevent it from coming back. I never asked for these two tests, since I'm already doing chemo so probably it doesn't matter now.

    · Share on FacebookShare on Twitter
  • keepthefaith
    keepthefaith Member Posts: 2,156
    edited December 2016

    mellee, I had the onco test and it came back intermediate...21. My MO said I could then do the mammaprint to see if I was high or low, since there is no intermediate. I didn't do the mammaprint. I think some Dr's use that protocol rather than doing the mammaprint initially. I am not sure if the markers of the mammaprint are different than the onco test or in addition to those. I guess you could contact the people who provide them...or maybe someone else knows and will chime in.

    · Share on FacebookShare on Twitter
  • mellee
    mellee Member Posts: 434
    edited December 2016

    I've looked into it and the markers are completely different for the two tests.

    This 2015 article (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC46036...) talks a little about it and how the results don't always match. For example, some people labeled as low risk in Oncotype are categorized as high risk in Mammaprint:

    Key differences between genomic assays

    A high rate of discordance has been observed between the MammaPrint and Oncotype DX assays. The results of a small, single-institution study conducted in France on patients who had both the MammaPrint assay and Oncotype assay showed that of patients in the MammaPrint high-risk group, ten of the 22 (45%) had a low RS, indicating minimal benefit from chemotherapy and only one of the 22 (5%) had a high RS. This discordance in risk assessment was reproduced in another study by Shivers et al, which directly compared MammaPrint, Oncotype DX, and Mammostrat. In this study, 33.3% of MammaPrint high-risk patients were classified as low risk by Oncotype DX and conversely 5.6% of low-risk MammaPrint patients were classified as high-risk RS. A direct comparison of PAM50 and Oncotype DX showed concordance for high RS and luminal B (high risk), as well as luminal A and low RS. However, more patients in the intermediate RS group were reclassified by PAM50 as low risk, suggesting that PAM50 may augment prognostic information provided by Onctoype DX alone.

    · Share on FacebookShare on Twitter

Categories